Bedrijfsoverzicht
Generate Biomedicines, Inc. is a biotechnology firm that operates within the healthcare sector, specifically focusing on the industry of biotechnology. The company engages in generative biology by utilizing machine learning to facilitate drug discovery and development through the programming of novel protein therapeutics in the United States. It employs protein-based modalities as its primary approach for advancing drug development initiatives. In terms of scale, the company holds a market capitalization of $1.45B and generates annual revenue of $31.89M with a workforce of 312 employees. The market cap figure of $1.45B suggests that investors are pricing the company based on future potential and intellectual property value rather than current profitability, while the revenue of $31.89M indicates an early-stage commercialization phase where sales are generated but have not yet achieved the scale to offset significant operational costs.
Financiële gezondheid
Generate Biomedicines, Inc. reported revenue of $31.89M for the trailing twelve months, yet posted a net income of -$249,523,008 and an EBITDA of -$221,887,008. The substantial gap between the positive revenue of $31.89M and the large negative net income reveals a cost structure where research, development, and operational expenses far exceed current sales revenue. The company recorded a free cash flow of -$119,101,624, which indicates a consumption of cash reserves to fund ongoing operations and research activities, thereby limiting immediate financial flexibility for expansion or dividends. Analysis of the three margin metrics shows a gross margin of 0.0%, an operating margin of -737.0%, and a profit margin of 0.0%. The negative operating margin of -737.0% highlights the intense burn rate typical of biotechnology firms in the discovery and development phase before products reach full commercial maturity. Regarding the balance sheet, the company has no debt and no specific cash balance listed, resulting in a debt-to-equity ratio that is N/A, which suggests a non-leveraged capital structure reliant on equity financing. The current ratio stands at 2.85, indicating that the company possesses 2.85 times the liquid assets required to cover its short-term liabilities, suggesting a conservative liquidity position despite the cash burn. Finally, the return on equity is -81.7% and the return on assets is -34.6%, revealing that management is currently generating negative returns on the capital invested in the business due to the lack of profitable earnings.
Waarderingsbeoordeling
The company presents a trailing P/E ratio of N/A and a forward P/E of -5.38. The difference between a non-existent trailing P/E and a negative forward P/E implies that the market is not valuing the stock based on historical earnings but is instead projecting future earnings that are currently negative, reflecting the high-risk nature of pre-revenue biotechnology assets. The price-to-book ratio is -0.93, which indicates that the market is pricing the company at a value below its book value, a common occurrence for unprofitable firms where assets may be overvalued on the books or where future earnings potential is discounted heavily. The price-to-sales ratio is 45.60, and the EV/EBITDA is N/A. These alternative valuation metrics suggest that investors are placing a high premium on every dollar of sales, expecting that current revenue will grow exponentially in the future to justify the high multiple. The stock's 52-week high is $15.32 and the 52-week low is $11.00. Without a specific current price listed in the available facts to calculate a precise percentage, the valuation is constrained within this trading range of $11.00 to $15.32, where the price-to-sales ratio of 45.60 implies a significant valuation relative to its sales base. The beta value is N/A, which means volatility data relative to the broader market is not available in the provided metrics, preventing a direct comparison of price swings against the S&P 500 or similar indices.
Growth & Income
The available data indicates that revenue growth year-over-year is N/A and earnings growth year-over-year is N/A. The inability to calculate growth rates from the provided TTM figures implies that the company is either in a transition period where comparable prior-year data is not available or that the business model is still evolving rapidly. For non-dividend payers, Generate Biomedicines, Inc. does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This means the company reinvests all available resources and any potential earnings back into research, development, and operational growth rather than distributing cash to shareholders. Given the negative net income and free cash flow, the concept of a sustainable payout ratio is irrelevant as the company retains all capital for operational needs. The overall growth and income profile is characterized by a focus on capital appreciation and potential future product launches rather than current income generation or revenue expansion metrics that can be quantified from the current reporting period.